AnaCardio

Solna, Sweden · $19.0M raised

Headquarters
Solna
Employees
1–10
Business Model
B2B
Total Funding
$19.0M
Last Round
$19.0M Venture RoundJan 2025
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

AnaCardio AB is a privately held clinical-stage biopharmaceutical company developing novel medicines for heart failure. Its lead program, AC01, is an oral ghrelin-mimetic small molecule and calcium-sensitizing inotrope licensed from Helsinn, which the company is developing as a contractile agent for heart-failure patients. The program originated in Karolinska Institutet research into improving heart-muscle contractility through a differentiated mechanism.

Summary

AnaCardio is a Biotech company based in Solna, Sweden. It has raised $19.0M in total across 1 round, most recently a $19.0M Venture Round in Jan 2025. Investors include Novo Holdings A/S, BB Pureos and Sound Bioventures.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Venture RoundFinancing RoundJan 2025
$19.0M

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

AnaCardio on Indexed.vc
<a href="https://indexed.vc/companies/anacardio"><img src="https://indexed.vc/api/badge/company/anacardio" alt="AnaCardio on Indexed.vc" width="260" height="76" /></a>